Share this Page:
Kidney cancer bone metastases in the long bones of the body are prone to fractures or bone pain needing treatment with radiotherapy or surgery. A review of the literature was conducted to find out whether the use of bisphosphonates in patients with kidney cancer bone metastases in the long bones results in a reduction in bone pain and/or fractures.
The literature review looked at all clinical studies on bisphosphonates in patients with kidney cancer metastases in the long bones. this resulted in 14 studies. In these studies, bisphosphonates reduced the average number of bone-related events (bone pain and/or fracture) by 0.4-0.95 events/year. The proportion of people who had bone pain and/or fracture was 38.3% across all 14 studies. When patients were treated with bisphosphonates and radiotherapy, this reduced to 18.4%. There was limited data on the rate of bone fractures.
In general, bisphosphonates reduce the rate of bone pain and/or fractures in patients with kidney cancer bone metastases. There is limited evidence for the effect of bisphosphonates on the rate of bone fractures in patients with kidney cancer metastases in the long bones.
